Skip to content

Study · Other design · 2003

1 result

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

Agersø H, Vicini P

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences1 Jun 2003Cited by 52 (Europe PMC)

PMID12791417 (opens in a new tab)DOI10.1016/s0928-0987(03)00073-3 (opens in a new tab)PepBankPUB-12791417
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanOther designMechanism

    In healthy volunteers, the pharmacodynamic model showed a dose-proportional effect of NN2211 (liraglutide) on the parameters that control beta-cell insulin secretion.

    In plain wordsIn healthy volunteers, liraglutide had an effect on insulin release that grew in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBeta-cell insulin secretion parameters
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    eight dose levels (values not stated)As given in this study (human).

    Source sentences

    Summary
    The analysis demonstrated a dose proportional effect of NN2211 on the parameters controlling beta cell insulin secretion.
    2 context sentences
    Summary · context
    In the present study, eight dose levels of NN2211 were tested in healthy human volunteers.
    Summary · context
    Placebo-dosed subjects were included in the analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01507272

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Novo Nordisk A/Sn = 34Mar 1999 to Dec 1999

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.